Novel approaches to tuberculosis vaccine development.
Tuberculosis (TB) remains the deadliest infectious disease. The widely used bacille Calmette-Guérin (BCG) vaccine offers only limited protection against TB. New vaccine candidates for TB include subunit vaccines and inactivated whole-cell vaccines, as well as live mycobacterial vaccines. Current developments in TB vaccines are summarized in this review.
Max Planck Institute for Infection Biology, Department of Immunology, Charitéplatz 1, 10117 Berlin, Germany. Electronic address: Kaufmann@mpiib-berlin.mpg.de.
Stefan H E
SH
Kaufmann
Max Planck Institute for Infection Biology, Department of Immunology, Charitéplatz 1, 10117 Berlin, Germany.
January
J
Weiner
Infectious Disease and International Health, Geisel School of Medicine, Hanover, New Hampshire, USA.
C Fordham
CF
von Reyn
D000818:Animals; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000276:immunology; D014376:Tuberculosis / Q000517:prevention & control; D032581:Tuberculosis Vaccines; D014613:Vaccines, Attenuated / Q000276:immunology
D032581:Tuberculosis Vaccines; D014613:Vaccines, Attenuated
Post-exposure vaccine; Pre-exposure vaccine; Preventive vaccine; Subunit vaccine; Therapeutic vaccine; Whole-cell vaccine